Trials / Completed
CompletedNCT03575052
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 784 (actual)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pimavanserin | Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets) |
| DRUG | Placebo | Placebo, tablets, once daily by mouth (provided as two placebo tablets) |
Timeline
- Start date
- 2018-05-21
- Primary completion
- 2022-05-06
- Completion
- 2022-05-06
- First posted
- 2018-07-02
- Last updated
- 2024-12-31
- Results posted
- 2024-12-31
Locations
104 sites across 12 countries: United States, Bulgaria, Colombia, Czechia, Georgia, Mexico, Poland, Romania, Russia, Serbia, South Africa, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03575052. Inclusion in this directory is not an endorsement.